Sensei Biotherapeutics’ (FTH) Buy Rating Reaffirmed at BTIG Research

Sensei Biotherapeutics (NASDAQ:FTH)‘s stock had its “buy” rating reaffirmed by research analysts at BTIG Research in a research note issued on Thursday,Benzinga reports. They currently have a $55.00 price target on the stock. BTIG Research’s price objective indicates a potential upside of 74.77% from the stock’s previous close.

A number of other equities analysts have also recently weighed in on FTH. Weiss Ratings began coverage on Sensei Biotherapeutics in a report on Wednesday, June 17th. They set a “sell (d-)” rating on the stock. Robert W. Baird initiated coverage on Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 target price for the company. Finally, HC Wainwright began coverage on shares of Sensei Biotherapeutics in a report on Monday, June 22nd. They issued a “buy” rating and a $60.00 price objective for the company. One investment analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $57.33.

Sensei Biotherapeutics Stock Down 5.0%

Shares of NASDAQ:FTH opened at $31.47 on Thursday. Sensei Biotherapeutics has a 52-week low of $6.32 and a 52-week high of $37.90. The firm has a market capitalization of $42.23 million, a P/E ratio of -0.22 and a beta of -0.26.

Sensei Biotherapeutics (NASDAQ:FTH) last released its quarterly earnings results on Friday, May 15th. The company reported ($131.45) earnings per share for the quarter. Sell-side analysts predict that Sensei Biotherapeutics will post -16.61 EPS for the current year.

Insider Transactions at Sensei Biotherapeutics

In other news, CEO Anand Kiran Parikh bought 2,806 shares of the company’s stock in a transaction dated Monday, June 22nd. The stock was bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the completion of the acquisition, the chief executive officer owned 764,234 shares in the company, valued at approximately $15,101,263.84. This trade represents a 0.37% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Brian C. Stephenson bought 9,391 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was acquired at an average cost of $26.13 per share, for a total transaction of $245,386.83. Following the completion of the purchase, the chief financial officer directly owned 26,804 shares of the company’s stock, valued at $700,388.52. The trade was a 53.93% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired 49,494 shares of company stock worth $1,188,822 in the last 90 days. Corporate insiders own 7.00% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing next-generation immunotherapies for cancer. The company applies its proprietary ImmunoPhage platform to create conditionally active biologics designed to stimulate the immune system in the tumor microenvironment while limiting activity in healthy tissue.

Its product pipeline has included experimental therapies such as solnerstotug (formerly SNS-101), a checkpoint inhibitor targeting VISTA, and additional oncology candidates in earlier stages of development.